The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products.
Excellent balance sheet and slightly overvalued.
Share Price & News
How has United Laboratories International Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 3933's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 3933 exceeded the Hong Kong Pharmaceuticals industry which returned 17.1% over the past year.
Return vs Market: 3933 exceeded the Hong Kong Market which returned -9.4% over the past year.
Price Volatility Vs. Market
How volatile is United Laboratories International Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall StAn Intrinsic Calculation For The United Laboratories International Holdings Limited (HKG:3933) Suggests It's 48% Undervalued
1 month ago | Simply Wall StWe're Not Counting On United Laboratories International Holdings (HKG:3933) To Sustain Its Statutory Profitability
1 month ago | Simply Wall StUnited Laboratories International Holdings (HKG:3933) Seems To Use Debt Quite Sensibly
Is United Laboratories International Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 3933 (HK$6.8) is trading below our estimate of fair value (HK$15.22)
Significantly Below Fair Value: 3933 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 3933 is poor value based on its PE Ratio (15.9x) compared to the Pharmaceuticals industry average (12.6x).
PE vs Market: 3933 is poor value based on its PE Ratio (15.9x) compared to the Hong Kong market (10x).
Price to Earnings Growth Ratio
PEG Ratio: 3933 is poor value based on its PEG Ratio (1.1x)
Price to Book Ratio
PB vs Industry: 3933 is overvalued based on its PB Ratio (1.5x) compared to the HK Pharmaceuticals industry average (1.1x).
How is United Laboratories International Holdings forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 3933's forecast earnings growth (14.9% per year) is above the savings rate (1.6%).
Earnings vs Market: 3933's earnings (14.9% per year) are forecast to grow slower than the Hong Kong market (17.5% per year).
High Growth Earnings: 3933's earnings are forecast to grow, but not significantly.
Revenue vs Market: 3933's revenue (7.2% per year) is forecast to grow slower than the Hong Kong market (11% per year).
High Growth Revenue: 3933's revenue (7.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 3933's Return on Equity is forecast to be low in 3 years time (11.5%).
How has United Laboratories International Holdings performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 3933 has high quality earnings.
Growing Profit Margin: 3933's current net profit margins (7.6%) are lower than last year (9.1%).
Past Earnings Growth Analysis
Earnings Trend: 3933's earnings have grown significantly by 36.4% per year over the past 5 years.
Accelerating Growth: 3933's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 3933 had negative earnings growth (-6%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6%).
Return on Equity
High ROE: 3933's Return on Equity (9.6%) is considered low.
How is United Laboratories International Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: 3933's short term assets (CN¥8.7B) exceed its short term liabilities (CN¥6.5B).
Long Term Liabilities: 3933's short term assets (CN¥8.7B) exceed its long term liabilities (CN¥2.6B).
Debt to Equity History and Analysis
Debt Level: 3933's debt to equity ratio (74.9%) is considered high.
Reducing Debt: 3933's debt to equity ratio has reduced from 86.3% to 74.9% over the past 5 years.
Debt Coverage: 3933's debt is well covered by operating cash flow (36%).
Interest Coverage: 3933's interest payments on its debt are well covered by EBIT (4.4x coverage).
What is United Laboratories International Holdings's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: 3933's dividend (1.13%) isn’t notable compared to the bottom 25% of dividend payers in the Hong Kong market (2.42%).
High Dividend: 3933's dividend (1.13%) is low compared to the top 25% of dividend payers in the Hong Kong market (7.05%).
Stability and Growth of Payments
Stable Dividend: 3933's dividend payments have been volatile in the past 10 years.
Growing Dividend: 3933's dividend payments have fallen over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (17.9%), 3933's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 3933's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
United Laboratories International Holdings has no CEO, or we have no data on them.
|Executive Chairman||7.25yrs||CN¥3.27m||0.90% CN¥109.3m|
|Vice Chairman||7.25yrs||CN¥3.17m||0.0012% CN¥146.9k|
|VP & Executive Director||9.67yrs||CN¥2.28m||0.000010% CN¥1.2k|
|VP & Executive Director||9.67yrs||CN¥2.28m||0.011% CN¥1.3m|
|Global Director of Intermediate & Bulk Medicine and Executive Director||7.08yrs||CN¥3.07m||0.0065% CN¥789.3k|
|VP & Executive Director||9.67yrs||CN¥2.28m||no data|
|Independent Non-Executive Director||13.17yrs||CN¥204.00k||no data|
|Independent Non-Executive Director||11.33yrs||CN¥204.00k||no data|
|Independent Non-Executive Director||7.58yrs||CN¥204.00k||no data|
Experienced Board: 3933's board of directors are considered experienced (9.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: 3933 insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 10.5%.
The United Laboratories International Holdings Limited's company bio, employee growth, exchange listings and data sources
- Name: The United Laboratories International Holdings Limited
- Ticker: 3933
- Exchange: SEHK
- Founded: 1990
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: HK$12.143b
- Shares outstanding: 1.81b
- Website: https://www.tul.com.cn
Number of Employees
- The United Laboratories International Holdings Limited
- 6 Fuk Wang Street
- Yuen Long Industrial Estate
- Yuen Long
- New Territories
- Hong Kong
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|3933||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Ordinary Shares||HK||HKD||Jun 2007|
|UNJ||DB (Deutsche Boerse AG)||Yes||Ordinary Shares||DE||EUR||Jun 2007|
|ULIH.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jun 2007|
|3933||SZSC (The Stock Exchange of Hong Kong - Shenzhen - Hong Kong Stock Connect)||Yes||Ordinary Shares||HK||HKD||Jun 2007|
The United Laboratories International Holdings Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products. It operates through three segments: Intermediate Products, Bulk Medicine, and Finished Products. The company offers oral antibiotics, antimicrobials for injection, anti-cold products, cough medicines, ophthalmic drugs, antiviral drugs, anti-hepatitis B drugs, diabetes drugs, skin drugs for external use, cardiovascular and cerebrovascular drugs, nervous system drugs, vitamins, and vacant gelatin capsules, as well as API and intermediate products. It also manufactures and sells soft capsules casings and organic fertilizers; holds trademarks; trades in pharmaceutical products; and engages in the food production activities. In addition, the company provides management services. It has operations in the People's Republic of China, Europe, India, Hong Kong, the Middle East, South America, other Asian regions, and internationally. The company was founded in 1990 and is headquartered in Yuen Long, Hong Kong. The United Laboratories International Holdings Limited is a subsidiary of Heren Far East Limited.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/07/02 12:41|
|End of Day Share Price||2020/07/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.